Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,096.00
Bid: 11,850.00
Ask: 12,400.00
Change: 0.00 (0.00%)
Spread: 550.00 (4.641%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,096.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TOP NEWS: Officials Investigate UK Strains Showing Worrying Mutation

Tue, 02nd Feb 2021 17:26

(Alliance News) - Public Health England is investigating strains of coronavirus in the UK which have developed a mutation that has been worrying scientists.

Eleven cases in the Bristol area have been identified as the variant that originally arose in Kent but are now showing the E484K mutation.

A cluster of 32 cases in Liverpool also have the same mutation but relate to the original strain of coronavirus that has been around since the start of the pandemic.

The South African variant – which also shows the mutation – is under investigation in at least eight postcode areas of England where cases not linked to travel have been found.

A PHE spokesman said: "PHE is monitoring the situation closely and all necessary public health interventions are being undertaken, including enhanced contact tracing and control measures."

The E484K mutation has been shown to reduce the effectiveness of vaccines in preventing people contracting Covid-19.

However, public health experts believe current vaccines will still be effective against strains with the mutation, although at a lower level, and are good at preventing severe disease.

Earlier, Health Secretary Matt Hancock said testing was now under way in postcode areas affected by the mutation, alongside eight postcode areas affected by the South African variant.

Speaking in the Commons, Hancock said the government is working closely with pharmaceutical firms in case vaccines need to be tweaked to accommodate new variants.

He said: "We're working with pharmaceutical companies and with the scientists to understand both whether the such modifications are needed, where they are needed, and how they can be brought to use on the frontline as quickly and safely as possible.

"This is obviously a very important consideration given the new variants that we've seen.

"And we have confidence that modifications to vaccines, should they be necessary in large scale, will be available more quickly than the original vaccines.

"And just as we did first time round, when we got in there early and we bought at risk, so we are having exactly the same conversations right now with the pharmaceutical companies to make sure that we are right at the front of this one."

Hancock told MPs that the aim of community testing for the South African variant – currently targeting around 80,000 people in eight postcode areas – is to "stop its spread altogether".

He said: "As with the variant first identified here in the UK, there is currently no evidence to suggest it is any more severe but we have to come down on it hard.

"Our mission must be to stop its spread altogether and break those chains of transmission."

Regarding the E484K mutation seen in the Kent variant, Jonathan Stoye, from the Francis Crick Institute, said the PHE report suggests the UK variant is now independently acquiring the E484K change.

"From a virological standpoint, appearance of new variants by mutation during replication cannot be considered surprising," he added.

"Whether this change will provide significant growth advantages for the novel virus causing it to predominate remains to be seen."

Julian Tang, honorary associate professor at the University of Leicester, described the finding as "a worrying development, though not entirely unexpected".

He said it is important that people follow lockdown rules to prevent opportunities for the virus to mutate further, suggesting that allowing spread could provide a "melting pot" for different emerging variants.

"We really need to reduce our contact rates to reduce the opportunities for viral spread (and) replication to reduce the speed with which these different virus variants can evolve," he added.

Clinical trials for two coronavirus vaccines – Novavax Inc and Johnson & Johnson – have shown the jabs offer some protection against variants with the E484K mutation.

However, they are less effective than against the variant that has been around since the start of the pandemic.

Laboratory studies also suggest vaccines developed by Moderna Inc and Pfizer Inc/BioNtech SE could work against variants, while variant checks against the Oxford University/AstraZeneca vaccine are ongoing.

Earlier, Andrew Hayward, professor of infectious disease epidemiology at University College London and a member of the Scientific Advisory Group for Emergencies, said a "sustainable strategy" will be needed in the future to tackle coronavirus mutations.

He said that, while it is sensible to try to stamp out chains of transmission of variants, new strains will continue to be a risk and suggested borders cannot stay shut forever.

Asked on Sky News about the probability of more strains entering the UK unless borders are closed completely, or unless all people entering the country are forced into hotel quarantine for 14 days, Hayward said: "Well, probably in the long term, 100%.

"The nature of this virus is that it will continue to mutate, as do all viruses, and new strains will emerge and they'll emerge in many different countries in the world at different times, and you won't notice that they are spreading until such time as they are quite widespread.

"The real challenge here is that, well, yes, you can think about completely shutting the borders or having quarantine, (but) what's the endgame in that?

"Is that something that you're going to do forever, because it looks like these strains may continue to arise in the long term?

"So we need some sort of sustainable strategy, and I think that's very difficult for politicians to think about that."

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
20 May 2024 11:55

LONDON MARKET MIDDAY: Gold shines amid interest rate cut hopes

(Alliance News) - Stock prices in London got a boost at midday on Monday, as investors eye a key UK inflation reading later in the week, which is expected to show cooling prices.

Read more
20 May 2024 08:24

TOP NEWS: AstraZeneca plans to build manufacturing plant in Singapore

(Alliance News) - AstraZeneca PLC on Monday announced plans for a USD1.5 billion manufacturing facility in Singapore to produce antibody drug conjugates, treatments that deliver "highly potent cancer-killing agents".

Read more
20 May 2024 07:47

LONDON BRIEFING: Keywords would back GBP2.0 billion bid as EQT circles

(Alliance News) - London's FTSE 100 is called to open higher at the start of the week, while the pound climbed and gold hit another record high, with investors hopeful the Federal Reserve could soon cut US interest rates.

Read more
20 May 2024 07:22

AstraZeneca announces $1.5bn Singapore manufacturing facility

(Sharecast News) - AstraZeneca announced plans to construct a $1.5bn manufacturing facility in Singapore on Monday, dedicated to the production of antibody drug conjugates (ADCs).

Read more
16 May 2024 10:27

AstraZeneca trials yield positive results for immunocompromised patients

(Alliance News) - AstraZeneca PLC on Thursday said results from recent trials revealed a significant reduction in cases of Covid-19.

Read more
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.